The TETAMI trial: The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: Methods and design

Journal of Thrombosis and Thrombolysis

Volumn 10, Issue 3, 2000, Pages 241-246

  Cohen, Marc ^a   Maritz, Frans ^b   Gensini, Gian Franco ^c   Danchin, Nicolas ^d   Timerman, Ari ^e   Huber, Kurt ^e   Gurfinkel, Enrique P ^f   White, Harvey ^g   Fox, Keith A A ^h   Vittori, Luc ^a   Le Louer, Veronique ^a   Bigonzi, Frederique ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b Karl Bremer Hospital   (South Africa)

^c Clinica Medica Generale e Cardiologia   (Italy)

^d University of Vienna ^*

^e UNIVERSITY OF VIENNA   (Austria)

^f GREEN LANE HOSPITAL   (New Zealand)

^g ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^h SANOFI   (France)

Author keywords

Acute myocardial infarction; Antithrombotic treatment; Enoxaparin; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; FACTORIAL ANALYSIS; FEMALE; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

ADULT; AGED; CLINICAL PROTOCOLS; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLACEBOS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; SURVIVAL RATE; TYROSINE;

EID: 17744384489     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026543107533     Document Type: Article

References (34)

1. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study
2. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
3. Role of thrombosis in atherosclerosis and its complications
4. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
5. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent primary angioplasty in myocardial infarction study group
6. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction
7. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction
8. Outcome of patients with acute myocardial infarction who are ineligible for primary angioplasty trials
9. Pharmacological activities of heparin chains: Should our past knowledge be revised?
10. Long-term persistence of biological activity following administration of enoxaparin sodium (Clexane) is due to sequestration of antithrombin-binding low molecular weight fragments: Comparison with unfractionated heparin
11. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIa receptor
12. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-q-wave coronary events study group
13. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
14. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
15. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
16. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
17. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes
18. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE investigators. Randomized efficacy study of tirofiban for outcomes and restenosis
19. Translation of clinical trials into practice: A European population-based study of the use of thrombolysis for acute myocardial infarction
20. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. National Registry of Myocardial Infarction
21. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction
22. Trends in the use of reperfusion therapy: Experience from the second National Registry of Myocardial Iwnfarction
23. The superiority of enoxaparin over UFH, evidenced in unstable angina/non-Q-wave MI patients, might also extend to Q-wave MI patient who did not receive lysis
24. Delayed hospital presentation in patients who have had acute myocardial infarction
25. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy
26. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?
27. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction
28. Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction
29. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
30. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction
31. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction
32. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute myocardial infarction: The fragmin in acute myocardial infarction (FRAMI) study
33. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction - A pilot study: Biochemical markers in acute coronary syndromes (BIOMACS II)